AYTU

Aytu BioPharma · USD

Market closed US (NYSE / Nasdaq) · 09:30–16:00 · Sun 22:02 · approx

Deep AI analysis (big model)

No deep analysis yet. Portfolio holdings are analysed automatically; for any other stock, click “Request deep AI analysis” above.

About Aytu BioPharma

Aytu BioPharma (AYTU) is a biopharmaceutical company focused on developing and commercializing treatments for respiratory diseases; however, I don't recognize it as a publicly traded company.

TickerAYTU
NameAytu BioPharma
CurrencyUSD

Reputation

🙂
How liked 50/100
From 0 recent analysed stories — 0 good · 0 bad · 0 neutral. Trend: stable.

Reputation builds as news about this company is analysed.

Price history & forecast

30-day forecast — Linear regression, Holt's exponential smoothing, and drift, plus a news-adjusted consensus (sentiment tilt +0.00). Estimates only, not advice.

Candlestick, volume & news sentiment

good bad neutral

Daily open/high/low/close candles with volume bars beneath; hover a candle for its OHLC, change and volume. Dots mark analysed news coloured by sentiment. Pick a range, or click-and-drag across the chart to zoom in.

Forecast accuracy (backtested)

No scored forecasts yet. Every visit records the day's forecast; once those predicted dates pass, this table fills in with how each method actually did (1 snapshot(s) recorded so far, none matured yet).

Technical analysis

BULLISH
61.54
RSI (14)i
2.20
SMA 20i
2.24
SMA 50i
1173981.94
SMA 200i
0.00%
1di
0.00%
1wi
-8.91%
1mi
5.49%
30d voli
11824390.00
52w highi
1.20
52w lowi
-100.00%
from highi
-46.69
MACDi
Downtrend (50d below 200d)MACD bullish crossover

Computed from 235 locally-stored price bars.

AI signals

  • HOLD 70% · long_term 2026-06-08 00:38

    The stock has been in a downtrend with significant volatility, indicated by recent close prices and the change over window. There are no recent positive headlines to support an immediate buy recommendation. The price action suggests caution is warranted until more positive indicators emerge.

    qwen2.5:3b

Related news

  • No matched headlines yet.